In a controlled cross-sectional cohort of 80 intact Beagles aged 1–11 years, immune aging proved heterogeneous and non-linear: absolute leukocyte counts declined in mid-life before rebounding in geriatric dogs, while serum cytokines showed sex-stratified patterns — more cytokines varied significantly with age in males than females, though age-by-sex interactions did not survive false-discovery-rate correction. In a separate 90-day intervention arm of 24 young Beagles, rapamycin produced the broadest cytokine endpoint response, canagliflozin (an SGLT2 inhibitor gaining longevity interest) showed narrower cytokine shifts alongside body-weight reduction, and dietary restriction reduced weight without measurably altering immune endpoints.
This work sits within a rapidly expanding canine geroscience agenda — dogs share human environments, disease patterns, and immune biology in ways rodents do not, making them attractive translational models. The rapamycin finding aligns with its established mTOR-suppressing immunomodulatory profile in rodent longevity studies; the canagliflozin signal is intriguing given recent human cardiovascular outcome data but remains mechanistically unresolved here. Critical limitations abound: small intervention groups, endpoint-only (not longitudinal) cytokine sampling, intact rather than neutered animals diverging from typical companion dogs, and no lifespan or healthspan outcomes. The authors themselves label the intervention arm exploratory. As a preprint posted on bioRxiv and not yet peer-reviewed, all findings should be treated as hypothesis-generating. Confirmatory longitudinal trials with functional aging endpoints are needed before any clinical translation.